Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.

Journal of the National Cancer Institute - 1 May 2017

Cortot Alexis B, Kherrouche Zoulika, Descarpentries Clotilde, Wislez Marie, Baldacci Simon, Furlan Alessandro, Tulasne David

Abstract excerpt

Inhibitors of the receptor tyrosine kinase (RTK) MET have been ineffective at treating cancer, possibly because of lack of knowledge that would allow selection of tumors likely to respond to this treatment. In contrast, specific epidermal growth factor receptor (EGFR) inhibitors have been used successfully against lung tumors displaying activating mutations in the kinase domain of EGFR. Recent publications...

Topics

Join the communities discussing this publication.

Biomarkers, Tumor
Exons
Gene Expression Regulation, Neoplastic
Molecular Targeted Therapy
Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Protein Kinase Inhibitors

Protein-Tyrosine Kinases

Proto-Oncogene Proteins c-met

Source

Identifiers

PMID: 28376232
DOI: 10.1093/jnci/djw262

Genes

MET
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.PMID 28376232Read ↗

Mechanistic insights into MET exon 14 skipping mutations and their role in tumor progression.Semantic proximity Read ↗

The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skippingSemantic proximity Read ↗

MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapySemantic proximity Read ↗

Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?Semantic proximity Read ↗

Recording and classifying MET receptor mutations in cancers.Semantic proximity Read ↗

MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-LifeSemantic proximity Read ↗

Non-small-cell lung cancer: how to manage MET exon 14 skipping mutant diseaseSemantic proximity Read ↗

MET alterations in NSCLC-Current Perspectives and Future Challenges.Semantic proximity Read ↗

[MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer].Semantic proximity Read ↗

[MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer].Semantic proximity Read ↗

MET Exon 14 Skipping Mutations: Essential Considerations for Current Management of Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

MET-dependent solid tumours - molecular diagnosis and targeted therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.